Platelet-activating factor synthesis pathway (PAF synthesis pathway)

The Platelet-activating factor (PAF) synthesis pathway encompasses the enzymatic reactions responsible for generating PAF (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine), a potent pro-inflammatory phospholipid mediator (Stafforini et al., 2003). Synthesis occurs via two distinct routes: the remodeling pathway, which is the primary source of PAF during inflammatory stimulation involving phospholipase A2 (PLA2) and lyso-PAF acetyltransferase (LPCAT), and the de novo pathway, which maintains basal PAF levels (Shindou et al., 2007). PAF exerts its biological effects by binding to the PAF receptor (PAFR), a G protein-coupled receptor, which triggers platelet aggregation, bronchoconstriction, and leukocyte activation (Honda et al., 2002). Dysregulation of the PAF synthesis pathway is implicated in a wide range of pathological conditions, including asthma, anaphylaxis, sepsis, and cardiovascular diseases such as atherosclerosis (Montrucchio et al., 2000). Therapeutic strategies targeting this pathway include the development of inhibitors for key enzymes like PLA2 or LPCAT2, as well as PAF receptor antagonists (Tsou et al., 2015). While several PAF receptor antagonists have been evaluated in clinical trials for conditions like acute pancreatitis and asthma, their clinical utility has been limited, with the exception of agents like Rupatadine used in allergic rhinitis. Understanding the specific enzymes within the synthesis pathway remains a critical area for developing targeted anti-inflammatory therapies.

Other names

PAF biosynthetic pathwayPAF remodeling pathwayPAF de novo pathwayPlatelet-activating factor metabolism

Inhibition of biosynthetic enzymes such as phospholipase A2 (PLA2) and lyso-PAF acetyltransferase (LPCAT) to reduce PAF production, or antagonism of the platelet-activating factor receptor (PAFR) to block downstream signaling (Stafforini et al., 2003; Shindou et al., 2007).